OncoTherapy Science, Inc.

DB:30O Stock Report

Market Cap: €53.9m

OncoTherapy Science Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Junichi Shimada

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure8.3yrs

Recent management updates

Recent updates

CEO

Junichi Shimada (63 yo)

2.3yrs

Tenure

Mr. Junichi Shimada is President, Chief Executive Officer of OncoTherapy Science, Inc. since July 2022 and serves as its Director from June 2022.

Board Members

NamePositionTenureCompensationOwnership
Hatsuo Kato
Executive Chairman47.6yrsno datano data
Junichi Shimada
President2.4yrsno datano data
Jae-Hyun Park
Chief Scientific Officer & Director6.4yrsno datano data
Yuichi Komine
Independent External Director10.2yrsno datano data
Miyako Takagi
External Auditor20.4yrsno data0.011%
€ 6.2k
Teruhisa Tajima
External Auditor10.2yrsno datano data
Yuka Yamane
Auditor3.4yrsno data0.018%
€ 9.9k
Yoshio Miki
Independent External Director2.4yrsno datano data

8.3yrs

Average Tenure

58yo

Average Age

Experienced Board: 30O's board of directors are considered experienced (8.3 years average tenure).